acitretin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	78	55079-83-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acitretin acitretinoin etretin neotigason soriatane isoacitretin isoetretin	An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate. Molecular weight: 326.44 Formula: C21H26O3 CLOGP: 6.07 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -5.83 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acitretin
acitretinoin
etretin
neotigason
soriatane
isoacitretin
isoetretin

An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.

Molecular weight: 326.44
Formula: C21H26O3
CLOGP: 6.07
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -5.83
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
35	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	59 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Oct. 28, 1996	FDA	STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	934.57	22.43	393	9938	86564	63392127
Skin haemorrhage	260.36	22.43	87	10244	10007	63468684
Skin exfoliation	205.86	22.43	112	10219	42990	63435701
Neurologic neglect syndrome	191.64	22.43	51	10280	2670	63476021
Carotid artery thrombosis	190.30	22.43	51	10280	2743	63475948
Personality disorder	153.44	22.43	51	10280	5760	63472931
Respiratory tract congestion	152.76	22.43	69	10262	17763	63460928
Adjustment disorder	147.69	22.43	43	10288	3135	63475556
Sinus congestion	139.18	22.43	65	10266	18058	63460633
Sneezing	138.85	22.43	65	10266	18153	63460538
Hemiplegia	129.90	22.43	51	10280	9272	63469419
Sensory loss	128.71	22.43	52	10279	10186	63468505
Affect lability	124.42	22.43	52	10279	11099	63467592
Motor dysfunction	122.82	22.43	51	10280	10710	63467981
Sinus disorder	120.48	22.43	65	10266	24488	63454203
Coordination abnormal	110.72	22.43	51	10280	13722	63464969
Psoriatic arthropathy	103.77	22.43	99	10232	91421	63387270
Rhinorrhoea	96.13	22.43	82	10249	65495	63413196
Muscle spasticity	91.30	22.43	52	10279	21742	63456949
Hemiparesis	88.10	22.43	52	10279	23230	63455461
Eating disorder	78.65	22.43	45	10286	18971	63459720
Aphasia	73.82	22.43	53	10278	32947	63445744
Cystitis	71.01	22.43	64	10267	54927	63423764
Arterial occlusive disease	63.83	22.43	27	10304	5931	63472760
Skin lesion	63.41	22.43	47	10284	30674	63448017
Gangrene	63.12	22.43	27	10304	6096	63472595
Influenza like illness	62.24	22.43	65	10266	66759	63411932
Influenza	61.65	22.43	82	10249	108640	63370051
Drug ineffective	61.51	22.43	332	9999	1044433	62434258
Skin plaque	61.26	22.43	29	10302	8291	63470400
Cutaneous T-cell lymphoma	61.15	22.43	18	10313	1362	63477329
Dysarthria	59.70	22.43	52	10279	42659	63436032
Oral lichen planus	58.63	22.43	15	10316	671	63478020
Infected dermal cyst	53.93	22.43	13	10318	454	63478237
Angina pectoris	53.24	22.43	42	10289	30036	63448655
Rash pustular	52.44	22.43	25	10306	7257	63471434
Dysphagia	52.04	22.43	68	10263	88517	63390174
Erythema	51.53	22.43	98	10233	175653	63303038
Rhesus antigen positive	51.31	22.43	10	10321	124	63478567
Pruritus	50.60	22.43	151	10180	361302	63117389
Pain of skin	44.04	22.43	26	10305	11608	63467083
Lichen planus	40.51	22.43	15	10316	2323	63476368
Squamous cell carcinoma	39.95	22.43	22	10309	8610	63470081
Erythrodermic psoriasis	39.57	22.43	12	10319	1006	63477685
Guttate psoriasis	39.05	22.43	10	10321	449	63478242
Dry skin	38.69	22.43	47	10284	56840	63421851
Oesophageal stenosis	35.65	22.43	15	10316	3251	63475440
Weaning failure	35.19	22.43	9	10322	402	63478289
Tongue ulceration	34.38	22.43	15	10316	3551	63475140
Skin fissures	34.31	22.43	22	10309	11366	63467325
Wrong technique in device usage process	34.25	22.43	15	10316	3583	63475108
Rebound psoriasis	34.20	22.43	7	10324	113	63478578
Cataract	33.80	22.43	44	10287	57009	63421682
Blood albumin increased	31.66	22.43	10	10321	959	63477732
Blood immunoglobulin M decreased	31.47	22.43	10	10321	978	63477713
Oesophageal ulcer	31.07	22.43	15	10316	4475	63474216
Arthritis	30.73	22.43	62	10269	115859	63362832
Dermatitis exfoliative generalised	30.28	22.43	14	10317	3793	63474898
Cerebrovascular accident	30.10	22.43	59	10272	107965	63370726
Toxicity to various agents	29.51	22.43	3	10328	247247	63231444
Burning sensation	29.22	22.43	40	10291	54367	63424324
Nasopharyngitis	28.91	22.43	99	10232	254158	63224533
Type IIb hyperlipidaemia	28.90	22.43	5	10326	30	63478661
Immunoglobulins decreased	28.84	22.43	10	10321	1282	63477409
Actinic keratosis	28.55	22.43	12	10319	2592	63476099
Diffuse alopecia	28.06	22.43	9	10322	907	63477784
Sunburn	27.76	22.43	12	10319	2776	63475915
Pustular psoriasis	27.68	22.43	14	10317	4612	63474079
Onychalgia	27.54	22.43	9	10322	962	63477729
Injection site bruising	27.48	22.43	34	10297	41876	63436815
Swelling	26.82	22.43	6	10325	275372	63203319
Infusion related reaction	26.81	22.43	4	10327	245517	63233174
Inflammatory bowel disease	26.67	22.43	13	10318	3960	63474731
Sticky skin	26.18	22.43	4	10327	9	63478682
Increased bronchial secretion	25.79	22.43	10	10321	1756	63476935
Face oedema	25.04	22.43	23	10308	20189	63458502
Skin infection	24.52	22.43	20	10311	14982	63463709
Tanning	24.18	22.43	5	10326	85	63478606
Palmoplantar pustulosis	24.09	22.43	7	10324	506	63478185
Skin atrophy	24.08	22.43	13	10318	4893	63473798
Intertrigo	22.83	22.43	7	10324	609	63478082
Blood immunoglobulin G decreased	22.59	22.43	10	10321	2448	63476243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	733.62	21.90	283	7075	38529	34911044
Drug ineffective	232.80	21.90	372	6986	456379	34493194
Vein rupture	179.14	21.90	41	7317	873	34948700
Skin plaque	176.31	21.90	57	7301	4557	34945016
Psoriatic arthropathy	126.32	21.90	68	7290	19730	34929843
Skin injury	114.72	21.90	35	7323	2310	34947263
Venous injury	105.87	21.90	22	7336	292	34949281
Injection site haemorrhage	96.05	21.90	45	7313	9723	34939850
Hepatic fibrosis	95.17	21.90	36	7322	4571	34945002
Anti-cyclic citrullinated peptide antibody positive	87.99	21.90	27	7331	1816	34947757
Erythrodermic psoriasis	87.43	21.90	23	7335	884	34948689
Joint ankylosis	83.49	21.90	25	7333	1547	34948026
Treatment failure	83.47	21.90	73	7285	46624	34902949
Bone cyst	83.06	21.90	25	7333	1575	34947998
Injection site papule	81.54	21.90	18	7340	323	34949250
Therapeutic product effect incomplete	78.50	21.90	73	7285	50468	34899105
Dermatitis exfoliative generalised	76.68	21.90	29	7329	3678	34945895
Drug intolerance	75.58	21.90	77	7281	59493	34890080
Hepatic cirrhosis	74.40	21.90	46	7312	17268	34932305
Pruritus	71.72	21.90	116	7242	141865	34807708
Cutaneous T-cell lymphoma	71.17	21.90	22	7336	1516	34948057
Injection site swelling	69.06	21.90	38	7320	11489	34938084
Pain of skin	69.01	21.90	31	7327	6078	34943495
Osteolysis	66.46	21.90	25	7333	3123	34946450
Red blood cell sedimentation rate abnormal	63.28	21.90	25	7333	3564	34946009
Hand deformity	62.38	21.90	25	7333	3700	34945873
Bone erosion	60.56	21.90	25	7333	3990	34945583
Squamous cell carcinoma	58.40	21.90	34	7324	11441	34938132
Inappropriate schedule of product administration	57.24	21.90	68	7290	62228	34887345
Alanine aminotransferase abnormal	56.83	21.90	25	7333	4663	34944910
Skin erosion	53.05	21.90	19	7339	2066	34947507
Gastrointestinal infection	51.75	21.90	25	7333	5773	34943800
Granuloma annulare	51.74	21.90	11	7347	164	34949409
Hypercholesterolaemia	47.35	21.90	27	7331	8735	34940838
Phototherapy	46.87	21.90	8	7350	32	34949541
Keratoacanthoma	46.35	21.90	13	7345	637	34948936
Squamous cell carcinoma of skin	44.43	21.90	28	7330	10853	34938720
C-reactive protein abnormal	42.19	21.90	25	7333	8685	34940888
Diabetes mellitus	39.50	21.90	49	7309	46824	34902749
Pityriasis rubra pilaris	38.72	21.90	8	7350	103	34949470
Localised infection	38.63	21.90	31	7327	17556	34932017
Myalgia	36.10	21.90	64	7294	84046	34865527
Hyperkeratosis	36.00	21.90	17	7341	3732	34945841
Hypertension	35.08	21.90	84	7274	136359	34813214
Pain in extremity	34.83	21.90	80	7278	126433	34823140
Arthropathy	34.47	21.90	35	7323	26872	34922701
Malignant melanoma stage I	33.89	21.90	7	7351	90	34949483
Basal cell carcinoma	33.62	21.90	30	7328	19628	34929945
Botryomycosis	33.43	21.90	6	7352	34	34949539
Induration	33.01	21.90	11	7347	964	34948609
Neuroendocrine tumour of the lung metastatic	32.70	21.90	7	7351	108	34949465
Skin exfoliation	32.11	21.90	34	7324	27398	34922175
Toxicity to various agents	31.35	21.90	3	7355	200359	34749214
Synovitis	31.33	21.90	25	7333	14041	34935532
Decreased immune responsiveness	30.77	21.90	12	7346	1652	34947921
Acute kidney injury	30.62	21.90	13	7345	304975	34644598
Emotional distress	29.88	21.90	25	7333	15001	34934572
Muscular weakness	29.39	21.90	54	7304	72843	34876730
Retinal disorder	29.05	21.90	10	7348	967	34948606
Musculoskeletal stiffness	28.91	21.90	42	7316	46638	34902935
Therapeutic product effect decreased	28.75	21.90	36	7322	34707	34914866
Macule	28.26	21.90	11	7347	1506	34948067
Transaminases increased	27.48	21.90	31	7327	26792	34922781
Hepatic steatosis	27.46	21.90	26	7332	18336	34931237
Drug-induced liver injury	25.67	21.90	31	7327	28801	34920772
Diffuse idiopathic skeletal hyperostosis	25.63	21.90	5	7353	47	34949526
Joint swelling	24.94	21.90	45	7313	59845	34889728
Hidradenitis	24.32	21.90	9	7349	1073	34948500
Death	23.17	21.90	30	7328	398019	34551554
Gastrointestinal tube insertion	23.14	21.90	9	7349	1230	34948343
Hypereosinophilic syndrome	22.69	21.90	6	7352	235	34949338
Insomnia	22.52	21.90	60	7298	103847	34845726
Sticky skin	22.40	21.90	3	7355	0	34949573
Erythema	22.07	21.90	54	7304	88726	34860847

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	1427.73	18.89	573	15732	89014	79639069
Skin haemorrhage	251.56	18.89	94	16211	11887	79716196
Drug ineffective	226.79	18.89	602	15703	1080311	78647772
Skin exfoliation	189.90	18.89	126	16179	54974	79673109
Neurologic neglect syndrome	172.28	18.89	50	16255	2857	79725226
Skin plaque	171.18	18.89	69	16236	10676	79717407
Carotid artery thrombosis	169.86	18.89	50	16255	3003	79725080
Psoriatic arthropathy	163.34	18.89	132	16173	77867	79650216
Vein rupture	147.65	18.89	41	16264	1995	79726088
Personality disorder	135.51	18.89	50	16255	6096	79721987
Respiratory tract congestion	127.52	18.89	68	16237	19886	79708197
Adjustment disorder	124.30	18.89	42	16263	3958	79724125
Cutaneous T-cell lymphoma	119.14	18.89	37	16268	2666	79725417
Sneezing	117.19	18.89	64	16241	19619	79708464
Sinus congestion	116.54	18.89	64	16241	19832	79708251
Sinus disorder	111.94	18.89	65	16240	22399	79705684
Affect lability	109.37	18.89	51	16254	11208	79716875
Sensory loss	105.40	18.89	52	16253	12939	79715144
Squamous cell carcinoma	104.81	18.89	55	16250	15567	79712516
Erythrodermic psoriasis	98.71	18.89	29	16276	1729	79726354
Dermatitis exfoliative generalised	96.70	18.89	41	16264	7200	79720883
Motor dysfunction	96.37	18.89	51	16254	14682	79713401
Pruritus	95.48	18.89	233	16072	394415	79333668
Injection site haemorrhage	94.18	18.89	63	16242	27807	79700276
Hemiplegia	92.89	18.89	50	16255	14889	79713194
Coordination abnormal	86.01	18.89	50	16255	17262	79710821
Venous injury	85.96	18.89	22	16283	780	79727303
Pain of skin	85.56	18.89	47	16258	14566	79713517
Muscle spasticity	78.52	18.89	51	16254	21424	79706659
Rhinorrhoea	78.49	18.89	87	16218	75987	79652096
Joint ankylosis	76.14	18.89	25	16280	2155	79725928
Skin lesion	75.46	18.89	65	16240	41779	79686304
Toxicity to various agents	70.12	18.89	4	16301	421536	79306547
Inappropriate schedule of product administration	69.35	18.89	109	16196	133519	79594564
Keratoacanthoma	66.49	18.89	19	16286	1026	79727057
Eating disorder	65.66	18.89	45	16260	20652	79707431
Skin injury	65.23	18.89	25	16280	3381	79724702
Bone cyst	65.04	18.89	25	16280	3408	79724675
Injection site papule	63.95	18.89	18	16287	920	79727163
Cystitis	62.65	18.89	65	16240	52667	79675416
Therapeutic product effect incomplete	59.38	18.89	105	16200	141540	79586543
Osteolysis	58.50	18.89	25	16280	4473	79723610
Influenza	58.14	18.89	99	16206	129507	79598576
Hemiparesis	57.99	18.89	51	16254	33682	79694401
Aphasia	54.43	18.89	57	16248	46675	79681408
Squamous cell carcinoma of skin	52.96	18.89	34	16271	13999	79714084
Erythema	50.86	18.89	129	16176	223161	79504922
Rhesus antigen positive	49.03	18.89	10	16295	124	79727959
Muscular weakness	48.83	18.89	104	16201	160625	79567458
Oral lichen planus	48.02	18.89	14	16291	812	79727271
Hepatic fibrosis	47.03	18.89	25	16280	7255	79720828
Arterial occlusive disease	46.22	18.89	26	16279	8430	79719653
Influenza like illness	45.05	18.89	64	16241	71643	79656440
Gangrene	44.81	18.89	26	16279	8938	79719145
Pityriasis rubra pilaris	44.17	18.89	9	16296	111	79727972
Induration	43.46	18.89	16	16289	1936	79726147
Skin erosion	42.75	18.89	20	16285	4425	79723658
Hyperkeratosis	42.71	18.89	24	16281	7766	79720317
Alanine aminotransferase abnormal	42.43	18.89	25	16280	8842	79719241
Acute kidney injury	42.42	18.89	27	16278	519377	79208706
Onychalgia	41.82	18.89	13	16292	939	79727144
Phototherapy	41.21	18.89	7	16298	28	79728055
Rebound psoriasis	39.46	18.89	9	16296	194	79727889
Pustular psoriasis	38.27	18.89	19	16286	4787	79723296
Granuloma annulare	37.81	18.89	11	16294	633	79727450
Guttate psoriasis	36.61	18.89	10	16295	457	79727626
Gastrointestinal infection	36.54	18.89	25	16280	11436	79716647
Hepatic cirrhosis	36.11	18.89	40	16265	34866	79693217
Arthritis	35.64	18.89	75	16230	114805	79613278
Cataract	35.47	18.89	53	16252	62067	79666016
Dysphagia	34.76	18.89	77	16228	122059	79606024
Rash pustular	34.48	18.89	24	16281	11287	79716796
Hypotension	34.43	18.89	24	16281	440293	79287790
Infected dermal cyst	34.37	18.89	12	16293	1246	79726837
Dyslipidaemia	33.87	18.89	24	16281	11609	79716474
Skin fissures	33.58	18.89	25	16280	13048	79715035
Skin disorder	33.58	18.89	38	16267	33905	79694178
Sticky skin	33.10	18.89	5	16300	7	79728076
Neuroendocrine tumour of the lung metastatic	32.84	18.89	7	16298	109	79727974
Death	32.42	18.89	41	16264	566473	79161610
Lichen planus	31.38	18.89	14	16291	2777	79725306
Anaemia	31.31	18.89	27	16278	444988	79283095
Neutropenia	31.18	18.89	10	16295	287700	79440383
Injection site swelling	30.98	18.89	43	16262	47089	79680994
Malignant melanoma stage I	30.91	18.89	7	16298	146	79727937
Localised infection	30.46	18.89	38	16267	37537	79690546
Nasopharyngitis	30.12	18.89	117	16188	253764	79474319
Skin atrophy	29.69	18.89	17	16288	5701	79722382
Dysarthria	29.44	18.89	51	16254	67571	79660512
Dry skin	29.23	18.89	51	16254	67944	79660139
Immunoglobulins decreased	28.27	18.89	11	16294	1549	79726534
Weaning failure	28.23	18.89	9	16296	706	79727377
Dizziness	28.18	18.89	40	16265	526401	79201682
Type IIb hyperlipidaemia	27.75	18.89	5	16300	30	79728053
Pain in extremity	27.53	18.89	147	16158	364391	79363692
Myalgia	27.50	18.89	92	16213	185549	79542534
Macule	27.50	18.89	13	16292	2944	79725139
Infusion related reaction	26.78	18.89	7	16298	230230	79497853
Psoriasis area severity index increased	26.78	18.89	6	16299	119	79727964
Bone erosion	26.77	18.89	25	16280	17822	79710261
Hypercholesterolaemia	26.58	18.89	28	16277	23067	79705016
Wrong technique in device usage process	26.49	18.89	14	16291	4014	79724069
Blood immunoglobulin M decreased	26.48	18.89	10	16295	1299	79726784
Somnolence	26.44	18.89	8	16297	238973	79489110
Tongue ulceration	25.97	18.89	14	16291	4179	79723904
Diffuse alopecia	25.51	18.89	9	16296	964	79727119
Oesophageal stenosis	25.47	18.89	14	16291	4340	79723743
Blood albumin increased	25.19	18.89	10	16295	1485	79726598
Diffuse idiopathic skeletal hyperostosis	25.15	18.89	5	16300	54	79728029
Cerebrovascular accident	24.83	18.89	79	16226	155213	79572870
Botryomycosis	24.74	18.89	5	16300	59	79728024
Dehydration	24.55	18.89	10	16295	248177	79479906
Gastric disorder	24.38	18.89	34	16271	37399	79690684
Angina pectoris	23.81	18.89	40	16265	51692	79676391
Decreased appetite	23.80	18.89	21	16284	342397	79385686
Hyponatraemia	23.57	18.89	4	16301	177844	79550239
Red blood cell sedimentation rate abnormal	23.39	18.89	25	16280	20938	79707145
Tanning	23.16	18.89	5	16300	83	79728000
Dyspnoea	22.89	18.89	94	16211	856931	78871152
Constipation	22.68	18.89	15	16290	283035	79445048
Platelet count decreased	22.48	18.89	6	16299	194658	79533425
Blood pressure increased	22.34	18.89	94	16211	211266	79516817
Tremor	22.16	18.89	4	16301	170079	79558004
Cutaneous symptom	22.13	18.89	7	16298	535	79727548
Inflammatory bowel disease	22.09	18.89	14	16291	5637	79722446
Palmoplantar pustulosis	21.63	18.89	7	16298	576	79727507
Seizure	21.47	18.89	6	16299	188828	79539255
Thrombocytopenia	21.33	18.89	14	16291	265245	79462838
Cellulitis	20.75	18.89	59	16246	109001	79619082
Tonsil cancer	20.33	18.89	8	16297	1160	79726923
Burning sensation	20.21	18.89	40	16265	58592	79669491
Contraindicated product administered	19.89	18.89	4	16301	157534	79570549
Rash	19.77	18.89	57	16248	578301	79149782
Pain	19.67	18.89	225	16080	703577	79024506
Oesophageal ulcer	19.41	18.89	14	16291	6961	79721122
Injection site bruising	19.26	18.89	32	16273	40970	79687113
Intertrigo	19.19	18.89	7	16298	825	79727258
Skin infection	19.03	18.89	21	16284	18224	79709859

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D05BB02	DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis
FDA CS	M0018962	Retinoids
FDA EPC	N0000175607	Retinoid
CHEBI has role	CHEBI:50176	keratolytic drugs
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Severe Recalcitrant Psoriasis	indication
Lichen planus	off-label use	4776004	DOID:9201
Keratosis follicularis	off-label use	48611009	DOID:2734
Lamellar ichthyosis	off-label use	205550003
Ichthyosiform erythroderma	off-label use	268282005
Primary cutaneous T-cell lymphoma	off-label use	400122007
Alcoholism	contraindication	7200002
Hypercholesterolemia	contraindication	13644009
Depressive disorder	contraindication	35489007
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Night blindness	contraindication	65194006	DOID:8499
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Diabetes mellitus	contraindication	73211009	DOID:9351
Premature epiphyseal closure	contraindication	89493005
Liver function tests abnormal	contraindication	166603001
Hypoalphalipoproteinemia	contraindication	190785000
Acute pancreatitis	contraindication	197456007	DOID:2913
Hypertrophy of bone	contraindication	203514008	DOID:205
Drug-induced hepatitis	contraindication	235876009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Psychiatric Disturbance	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST			WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST			CHEMBL	CHEMBL
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	4.74	CHEMBL
Bile salt export pump	Transporter		ABCBB_RAT		IC50	4.71	CHEMBL

External reference:

ID	Source
4021061	VUID
N0000148524	NUI
D02754	KEGG_DRUG
16818	RXNORM
C0050559	UMLSCUI
CHEBI:50173	CHEBI
CHEMBL1131	ChEMBL_ID
DB00459	DRUGBANK_ID
D017255	MESH_DESCRIPTOR_UI
5284513	PUBCHEM_CID
7598	IUPHAR_LIGAND_ID
5530	INN_ID
69427-46-9	SECONDARY_CAS_RN
LCH760E9T7	UNII
108914001	SNOMEDCT_US
386938006	SNOMEDCT_US
4021061	VANDF
11379	MMSL
117161	MMSL
4128	MMSL
d03836	MMSL
004121	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1135	CAPSULE	10 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1136	CAPSULE	25 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1138	CAPSULE	17.50 mg	ORAL	ANDA	24 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1750	CAPSULE	10 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1750	CAPSULE	10 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1751	CAPSULE	17.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1751	CAPSULE	17.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1752	CAPSULE	22.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1752	CAPSULE	22.50 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1753	CAPSULE	25 mg	ORAL	ANDA	17 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1753	CAPSULE	25 mg	ORAL	ANDA	17 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0090	CAPSULE	10 mg	ORAL	NDA	27 sections
SORIATANE	HUMAN PRESCRIPTION DRUG LABEL	1	0145-0091	CAPSULE	25 mg	ORAL	NDA	27 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7020	CAPSULE	10 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
Acitretin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7023	CAPSULE	25 mg	ORAL	ANDA	28 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-086	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-087	CAPSULE	17.50 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42291-088	CAPSULE	25 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-080	CAPSULE	10 mg	ORAL	ANDA	25 sections
ACITRETIN	HUMAN PRESCRIPTION DRUG LABEL	1	42794-080	CAPSULE	10 mg	ORAL	ANDA	25 sections